Brief: Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients
27/05/2026 13:18
BRIEF-Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients May 27 (Reuters) - Corcept Therapeutics Inc CORT.O:
TO RESUBMIT ITS NEW DRUG APPLICATION FOR RELACORILANT AS A TREATMENT FOR PATIENTS WITH CUSHING’S SYNDROME
FDA EXPECTS PDUFA DATE SIX MONTHS AFTER NDA RESUBMISSION FOR RELACORILANT
Source text: ID:nBw2FWxM2a
Further company coverage: CORT.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Corcept Therapeutics
See all newsU.S. RESEARCH ROUNDUP-Salesforce, Snowflake, Zscaler
Brief: Corcept To Resubmit NDA For Relacorilant As Treatment For Cushing's Syndrome Patients
U.S. RESEARCH ROUNDUP- Caterpillar, Textron, Wesco International
Corcept Q1 revenue rises but misses analyst estimates
Brief: Corcept Therapeutics Q1 EPS USD -0.3